Novel human mPGES-1 inhibitors identified through structure-based virtual screening.

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Computational Biology

Background:

• Microsomal prostaglandin E synthase-1 (mPGES-1) is a key enzyme in inflammatory pathways, making it a therapeutic target for inflammatory disorders.
• Developing novel mPGES-1 inhibitors with unique chemical structures is crucial for next-generation anti-inflammatory drugs.

Purpose of the Study:

• To identify novel mPGES-1 inhibitors with new scaffolds using structure-based drug design.
• To validate computationally identified compounds through in vitro assays.

Main Methods:

• Employed large-scale structure-based virtual screening using a 3D model of mPGES-1 in its open state.
• Utilized flexible docking, molecular dynamics simulations, and binding free energy calculations for compound selection.
• Performed in vitro assays to confirm the inhibitory activity of selected compounds against mPGES-1.

Main Results:

• Successfully identified novel mPGES-1 inhibitors with previously undiscovered scaffolds.
• The compound (Z)-5-benzylidene-2-iminothiazolidin-4-one emerged as a promising scaffold for further drug development.
• Experimental validation confirmed the inhibitory activity of the computationally selected compounds.

Conclusions:

• The study demonstrates the successful application of a 3D structural model of open-state mPGES-1 for virtual screening.
• This approach led to the discovery of novel chemical scaffolds for mPGES-1 inhibitors.
• The findings support the use of the modeled mPGES-1 structure for future structure-based drug design and discovery of anti-inflammatory agents.